Precision BioSciences, Inc. (DTIL)

NCM – Real Time Price. Currency in USD

7.45

-0.06 (-0.80%)

Market open: Aug 12, 2026, 2:03 PM EDT

7.51

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

06.08.2026

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. “The second quarter marked a defining moment for Precision BioSciences and the hepatitis B field, with the first clinical biopsy evidence that a therapeutic.

Videos

No Data

There is no data to display

Press releases

06.08.2026

Precision BioSciences, Inc. (DTIL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Precision BioSciences, Inc. (DTIL)

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Videos

No Data

Press releases

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Videos

No Data

Press releases

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Search stocks

Precision BioSciences, Inc. (DTIL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Precision BioSciences, Inc. (DTIL)

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Videos

No Data

Press releases

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Videos

No Data

Press releases

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update